Neflamapimod is under clinical development by CervoMed and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Neflamapimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Neflamapimod overview

Neflamapimod (VX-745) is under development for the treatment of Alzheimer’s disease, Lewy body dementia, cognitive defects in Huntington disease, acute ischemic stroke and Down syndrome. The drug candidate is administered through oral route as a hard gelatin capsule. It acts by targeting alpha isoform of the protein enzyme p38 mitogen-activated protein kinase (p38 MAPK alpha). It was also under development for the treatment of rheumatoid arthritis.

CervoMed overview

CervoMed, formerly Diffusion Pharmaceuticals Inc, is a clinical-stage biotechnology company. It develops standard-of-care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA orphan-designated indications. It offers new and small-molecule drugs for regulating the movement of oxygen into tissue and treatment for stroke, treatment-resistant cancerous tumors, glioblastoma multiforme, pancreatic cancer, and brain metastases. CervoMed develops trans sodium crocetinate, a synthetic small molecule that improves the diffusion of oxygen into hypoxic tissue and sensitizes the tumor to radiation therapy. The company offers products for cancer, stroke and heart attack. It performs clinical studies on pancreatic cancer and brain metastasis through cancer centers. CervoMed is headquartered in Charlottesville, Virginia, the US.

For a complete picture of Neflamapimod’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.